Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Magen BioSciences Inc.

Division of Pharmaceutical Product Development Inc.
www.magenbiosciences.com

Latest From Magen BioSciences Inc.

The A-List: 2009's Trend-Shaping Series A Financings

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
BioPharmaceutical Medical Device

Start-Up Quarterly Statistics, Q2 2009

Highlights from the Q2 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $864 million--a 25% increase from Q1 2009--with most of the money, 54% or $465 million, coming out of the device industry, which saw only $127 million the previous quarter. There was one acquisition--PPD paid $14.5 million in cash for Magen BioSciences. In the most significant alliance, valued at up to $527 million, GSK got rights to three compounds from Concert Pharmaceuticals, including two in the preclinical stage, which was the most popular phase of development on Q2 alliances.
BioPharmaceutical Medical Device

PPD buys Magen BioSciences and sells anticancer research centre

PPD will expand into the dermatology market and move away from preclinical oncology research in a realignment towards its core operations.

Dermatology Companies

Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors

The annual JP Morgan conference has always been a stage for reviewing new solutions to the basic business-model problem of biotechnology. But as Big Pharma's troubles have grown, the conference has also become a showcase for large drug company problems. The quick fix: keep shareholders in the stocks by returning cash to them. Medium term: adopt one of four basic business models. Longer term: disaggregate.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pharmaceutical Product Development Inc.
  • Senior Management
  • Brian M Gallagher, PhD, Pres. & CEO
    Cyrus Mozayeni, MD, Dir., Bus. Dev.
  • Contact Info
  • Magen BioSciences Inc.
    Phone: (781) 314-2900
    100 Beaver St.
    Ste. 101
    Waltham, MA 02453
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register